Table 3.
Number and proportion of patients who suffered a hip fracture and were prescribed antiosteoporotic treatment* within 90 days after hospital discharge, by sex and age
| Basque Country (2017–2021) | Catalonia (2010–2018) | Navarre (2014–2021) | Valencia Region (2008–2020) | PREV2FO National Cohort | |
|---|---|---|---|---|---|
| N | 9519 | 56,627 | 4419 | 50,905 | 121,470 |
| Treatment by sex and age: n (%) | |||||
| Sex | |||||
| Men | 714 (34.3%) | 1625 (12.0%) | 198 (19.9%) | 1587 (12.6%) | 4124 (14.1%) |
| Women | 2845 (38.3%) | 9060 (21.0%) | 924 (27.0%) | 9611 (25.1%) | 22,440 (24.3%) |
| Age group | |||||
| 65–74 | 505 (48.0%) | 1315 (22.9%) | 121 (28.6%) | 1729 (25.2%) | 3670 (26.1%) |
| 75–84 | 1337 (46.1%) | 4809 (23.4%) | 435 (29.1%) | 5540 (25.5%) | 12,121 (26.0%) |
| 85 + | 1717 (30.8%) | 4561 (15.0%) | 566 (22.6%) | 3929 (17.6%) | 10,773 (17.7%) |
*At least one prescription within 90 days after hospital discharge